Get to know our clinical trials

Trial of RAS(ON) inhibitor combinations in patients with RAS-mutated non-small cell lung cancer (NSCLC).

THE AIM OF THIS SUBSTUDY IS TO TEST THE SAFETY OF AN EXPERIMENTAL DRUG, CALLED RMC.6291, IN COMBINATION WITH THE ALREADY LICENSED DRUG, PEMBROLIZUMAB (KEYTRUDAR) (THESE ARE THE TWO STUDY DRUGS).

Imagen del Dr. Mariano Ponz -Sarvisé, especialista en Oncología Médica de la Clínica Universidad de Navarra. El Dr. Ponz-Sarvisé se dedica preferencialmente a los tumores de páncreas y vías biliares.
Dr. Mariano Ponz-Sarvisé Curriculum
Specialist Medical Oncology Department
Navarre headquarters
Cancer Center
Lung Cancer Area
Status
In recruitment
headquarters
Pamplona/Madrid
Early phase

Technical Summary

  • PLATFORM STUDY OF RAS(ON) INHIBITOR COMBINATIONS IN PATIENTS WITH RAS-MUTATED NON-SMALL CELL LUNG CANCER (NSCLC).
  • Code EudraCT: 2023-509571-16-00
  • Protocol number: RMC-LUNG-101
  • Promoter: Revolution Medicines, Inc.

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

More information about this clinical trial

Information offered by the Spanish Registry of Clinical Studies

  • Summary
  • Information
  • Calendar
  • Headquarters
  • Drugs
Read more about this clinical trial
Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION